Matthew P. Braun

2.6k total citations
42 papers, 1.5k citations indexed

About

Matthew P. Braun is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Matthew P. Braun has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Organic Chemistry, 15 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Matthew P. Braun's work include Drug Transport and Resistance Mechanisms (10 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Inflammatory mediators and NSAID effects (5 papers). Matthew P. Braun is often cited by papers focused on Drug Transport and Resistance Mechanisms (10 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Inflammatory mediators and NSAID effects (5 papers). Matthew P. Braun collaborates with scholars based in United States, Japan and Germany. Matthew P. Braun's co-authors include Carl R. Johnson, C. B. W. Senanayake, Joseph P. Adams, Dennis Dean, Milan R. Uskoković, Peter M. Wovkulich, Ralph A. Stearns, Xiaoyan Chu, Raymond Evers and Shuet-Hing Lee Chiu and has published in prestigious journals such as Journal of the American Chemical Society, European Heart Journal and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Matthew P. Braun

41 papers receiving 1.4k citations

Peers

Countries citing papers authored by Matthew P. Braun

Since Specialization

Citations

This map shows the geographic impact of Matthew P. Braun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew P. Braun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew P. Braun more than expected).

Fields of papers citing papers by Matthew P. Braun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew P. Braun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew P. Braun. The network helps show where Matthew P. Braun may publish in the future.

Co-authorship network of co-authors of Matthew P. Braun

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew P. Braun. A scholar is included among the top collaborators of Matthew P. Braun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew P. Braun. Matthew P. Braun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models 2023 ·European Heart Journal ·(unknown), Jamie E. DeNizio, (unknown), Chaitali Dutta, Victoria Clendaniel, Ryan Garrity, Nancy J. Cox, Zachary Glass, (unknown), Matthew P. Braun, (unknown), (unknown), Sekar Kathiresan, Andrew M. Bellinger, Amit V. Khera	8
2	Lymphatic Absorption, Metabolism, and Excretion of a Therapeutic Peptide in Dogs and Rats 2013 ·Drug Metabolism and Disposition ·Yan Zou, Thomas J. Bateman, C. M. Adreani, Xiaolan Shen, Paul Cunningham, Bo Wang, (unknown), (unknown), Xuening Hong, Christian Nunes da Silva, (unknown), (unknown), (unknown), Matthew P. Braun, Sanjeev Kumar, (unknown)	20
3	Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant 2010 ·Cancer Chemotherapy and Pharmacology ·S. Aubrey Stoch, Cynthia Gargano, J L Valentine, Matthew P. Braun, M. Gail Murphy, (unknown), Anup Majumdar, Edward Pequignot, Keith Gottesdiener, Kevin J. Petty, Deborah Panebianco, Dennis Dean, Walter K. Kraft, Howard Greenberg	13
4	Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans 2009 ·Drug Metabolism and Disposition ·Sanjeev Kumar, (unknown), Georgy Hartmann, (unknown), Arthur Bergman, (unknown), Jonathan Z. Ho, (unknown), (unknown), Matthew P. Braun, Bindhu V. Karanam, Dennis Dean, Isaias Noel Gendrano, (unknown), John A. Wagner, Rajesh Krishna	33
5	Multiple strategies for the preparation of a sulfur-35 labeled NPC1L1 radioligand 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Matthew P. Braun, Joseph F. Leone, Peter Lin, Robert J. DeVita, Margarita García‐Calvo, (unknown), JeanMarie Lisnock, Dennis Dean	5
6	Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys 2009 ·Drug Metabolism and Disposition ·(unknown), Georgy Hartmann, Qing Chen, (unknown), Scott A. Bradley, George A. Doss, (unknown), Jonathan Z. Ho, Matthew P. Braun, Dennis Dean, Wei Tang, Sanjeev Kumar	27
7	Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters 2008 ·Pharmaceutical Research ·Xiaoyan Chu, Yuexia Liang, Xiaoxin Cai, (unknown), (unknown), Kelem Kassahun, Magang Shou, Matthew P. Braun, George A. Doss, M. Reza Anari, Raymond Evers	16
8	Madin-Darby Canine Kidney II Cells: A Pharmacologically Validated System for NPC1L1-Mediated Cholesterol Uptake 2008 ·Molecular Pharmacology ·Adam B. Weinglass, Martin Köhler, (unknown), Jessica Liu, William A. Schmalhofer, (unknown), Brande S. Williams, (unknown), L.Kent Smith, (unknown), Kelly Bleasby, Joseph F. Leone, Yui S. Tang, Matthew P. Braun, Feroze Ujjainwalla, Margaret E. McCann, Gregory J. Kaczorowski, María L. García	22
9	In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations 2007 ·Drug Metabolism and Disposition ·Ying Li, J. Greg Slatter, Zhoupeng Zhang, Yan Li, George A. Doss, Matthew P. Braun, Ralph A. Stearns, Dennis Dean, Thomas A. Baillie, Wei Tang	34
10	Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Xiaoyan Chu, Kelly Bleasby, Jocelyn Yabut, Xiaoxin Cai, Grace Chan, Michael J. Hafey, Shiyao Xu, Arthur Bergman, Matthew P. Braun, Dennis Dean, Raymond Evers	143
11	Synthesis of [phenyl-U-14C]aryl and [8-14C]carboxy labeled tracers of vorinostat 2006 ·Journal of Labelled Compounds and Radiopharmaceuticals ·(unknown), Matthew P. Braun	4
12	Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABAA α5 inverse agonist for cognitive dysfunction 2005 ·Bioorganic & Medicinal Chemistry Letters ·Philip Jones, John Atack, Matthew P. Braun, (unknown), Mark S. Chambers, Desmond O’Connor, Susan M. Cook, Sarah C. Hobbs, (unknown), (unknown), (unknown), Keith A. Wafford, Angus M. MacLeod	18
13	EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS 2005 ·Drug Metabolism and Disposition ·Qing Chen, George A. Doss, (unknown), (unknown), Yui S. Tang, Matthew P. Braun, (unknown), John R. Strauss, Regina W. Wang, Ralph A. Stearns, David C. Evans, Thomas A. Baillie, Wei Tang	38
14	Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Xiaoyan Chu, (unknown), Matthew P. Braun, Balázs Sarkadi, David Evans, Raymond Evers	80
15	IN VITRO AND IN VIVO METABOLISM OF A POTENT AND SELECTIVE INTEGRIN αvβ3 ANTAGONIST IN RATS, DOGS, AND MONKEYS 2004 ·Drug Metabolism and Disposition ·Donghui Cui, Raju Subramanian, Magang Shou, Xiao Yu, Michael A. Wallace, Matthew P. Braun, Byron H. Arison, James A. Yergey, Thomayant Prueksaritanont	12
16	BIOACTIVATION OF THE 3-AMINO-6-CHLOROPYRAZINONE RING IN A THROMBIN INHIBITOR LEADS TO NOVEL DIHYDRO-IMIDAZOLE AND IMIDAZOLIDINE DERIVATIVES: STRUCTURES AND MECHANISM USING 13C-LABELS, MASS SPECTROMETRY, AND NMR 2003 ·Drug Metabolism and Disposition ·Raju Subramanian, (unknown), Jonathan Z. Ho, Steven M. Pitzenberger, Maria Victoria Silva Elipe, Christopher R. Gibson, Matthew P. Braun, Xiao Yu, (unknown), Rominder Singh	9
17	Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Sanjeev Kumar, Koppara Samuel, S. Ramaswamy, Matthew P. Braun, Ralph A. Stearns, Shuet-Hing Lee Chiu, David C. Evans, Thomas A. Baillie	138
18	High-throughput simultaneous determination of the HIV protease inhibitors indinavir and L-756423 in human plasma using semi-automated 96-well solid phase extraction and LC–MS/MS 2000 ·Journal of Pharmaceutical and Biomedical Analysis ·Mark J. Rose, (unknown), (unknown), Eric Woolf, K. C. Yeh, Li Lin, Wei Fang, John Y.‐K. Hsieh, Matthew P. Braun, Gregory J. Gatto, B.K. Matuszewski	25
19	Studies on Cytochrome P-450-Mediated Bioactivation of Diclofenac in Rats and in Human Hepatocytes: Identification of Glutathione Conjugated Metabolites 1999 ·Drug Metabolism and Disposition ·Wei Tang, Ralph A. Stearns, Stelvio M. Bandiera, Yong Zhang, Conrad E. Raab, Matthew P. Braun, Dennis Dean, Jianmei Pang, Kwan Leung, George A. Doss, John R. Strauss, Gloria Y. Kwei, Thomas H. Rushmore, Shuet-Hing Lee Chiu, Thomas A. Baillie	139
20	Antiatherosclerotic Effects of Oral Naftidrofuryl in Cholesterol-Fed Rabbits Involve Inhibition of Neutrophil Function 1995 ·Journal of Cardiovascular Pharmacology ·Peter Kienbaum, Matthew P. Braun, (unknown), (unknown), Mario Sarbia, Karsten Schrör	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact